KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Novavax (NVAX) EBT (2016 - 2025)

Historic EBT for Novavax (NVAX) over the last 17 years, with Q3 2025 value amounting to -$203.0 million.

  • Novavax's EBT fell 6597.13% to -$203.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $350.7 million, marking a year-over-year increase of 22536.26%. This contributed to the annual value of -$176.6 million for FY2024, which is 6747.61% up from last year.
  • As of Q3 2025, Novavax's EBT stood at -$203.0 million, which was down 6597.13% from $107.5 million recorded in Q2 2025.
  • In the past 5 years, Novavax's EBT registered a high of $519.8 million during Q1 2025, and its lowest value of -$829.7 million during Q4 2021.
  • Its 5-year average for EBT is -$140.2 million, with a median of -$166.1 million in 2022.
  • In the last 5 years, Novavax's EBT tumbled by 189057.7% in 2021 and then skyrocketed by 45780.38% in 2025.
  • Over the past 5 years, Novavax's EBT (Quarter) stood at -$829.7 million in 2021, then skyrocketed by 77.76% to -$184.5 million in 2022, then grew by 4.23% to -$176.7 million in 2023, then skyrocketed by 58.36% to -$73.6 million in 2024, then crashed by 175.94% to -$203.0 million in 2025.
  • Its EBT was -$203.0 million in Q3 2025, compared to $107.5 million in Q2 2025 and $519.8 million in Q1 2025.